Dr. Eduardo Gutiérrez is a Senior Consultant in the Nephrology Department at Hospital 12 de Octubre in Madrid, a permanent position he has held since March 2013 after ranking first in the national competitive examination. He has extensive experience in the study of glomerular diseases (GLOSEN, RedinRen), with a particular focus on IgA nephropathy (IgAN). He led the first prospective, randomized trial demonstrating the benefits of renin–angiotensin–aldosterone system blockade on renal prognosis in patients with IgAN (J Am Soc Nephrol 2003).

His research has contributed to the understanding of the pathophysiological mechanisms of macroscopic hematuria, provided the first worldwide validation of the Oxford Classification in IgAN patients with “benign” presentation (J Am Soc Nephrol 2012; SENEFRO Research Award 2013), and clarified the clinical consequences of hematuria relapses. He has also published data from the Spanish National Registry on IgAN (Nephrol Dial Transplant 2017) and actively participated in the European VALIGA study, which validated the Oxford histological classification, leading to several influential publications that shaped the clinical and therapeutic approach to IgAN.

Dr. Gutiérrez has further collaborated on multicenter studies showing the prognostic value of complement activation pathways in IgAN, including work with Professor Santiago Rodríguez de Córdoba’s Complement Study Group in Spain and with Matthew Pickering and Nicholas Medjeral Thomas in the UK. Since 2017, he has been responsible for the clinic on genetic and hereditary kidney diseases at Hospital 12 de Octubre. He also contributed to the REPRISE study validating tolvaptan use in polycystic kidney disease, and in recent years has focused on cystic kidney diseases, investigating type IV collagen disorders as potential prognostic markers in collaboration with Ashima Gulati at Yale University (Kidney Int Rep 2019).